- Home
- OSS vs MSLE Comparison
OSS vs MSLE Comparison
Compare OSS & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSS | MSLE |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 144.6M |
| IPO Year | 2017 | 2007 |
Fundamental Metrics
Financial Performance| Metric | OSS | MSLE |
|---|---|---|
| Price | $4.35 | $7.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $15.33 | ★ $24.17 |
| AVG Volume (30 Days) | ★ 1.3M | 39.6K |
| Earning Date | 10-28-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,027,382.00 | N/A |
| Revenue This Year | $39.68 | N/A |
| Revenue Next Year | $16.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $4.17 | $5.44 |
| 52 Week High | $20.88 | $13.39 |
Technical Indicators
Market Signals| Indicator | OSS | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 27.58 | 50.66 |
| Support Level | N/A | $6.60 |
| Resistance Level | $7.13 | $7.19 |
| Average True Range (ATR) | 0.45 | 0.50 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 13.85 | 75.74 |
Price Performance
Historical ComparisonAbout OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.